<HashMap><database>GNPS</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://massive-ftp.ucsd.edu/v02/MSV000082714/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Metabolomics</omics_type><submitter>Maureen Kachman</submitter><instrument_platform>QTOF - NEGATIVE</instrument_platform><instrument_platform>QTOF - POSITIVE</instrument_platform><species>Homo Sapiens</species><full_dataset_link>https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=4773717a2b1e49819eda9bf37b17393c</full_dataset_link><submitter_email>mkachman@med.umich.edu</submitter_email><submitter_affiliation>University of Michigan</submitter_affiliation><sample_protocol></sample_protocol><repository>GNPS</repository><file_size>259</file_size><ptm_modification>MS:1002864 - No post-translational-modifications are included in the identified peptides of this dataset</ptm_modification><data_protocol></data_protocol></additional><is_claimable>false</is_claimable><name>Metabolomics Workbench ST000677 - GNPS - Nonalcoholic steatohepatitis (NASH) changes with S.Q. Leptin administrations</name><description>Samples are from individuals with documented fatty liver disease (NAFLD) from whom serum was drawn at baseline and after 1 and 12 months of S.Q. Leptin administrations. The effect of leptin on degree of steatosis and inflammation was assessed in liver biopsies at baseline and following 1 year of treatment.</description><dates><publication>Thu Aug 02 17:17:00 BST 2018</publication></dates><accession>MSV000082714</accession><cross_references><TAXONOMY>9606</TAXONOMY></cross_references></HashMap>